Contact us

Information for clinicians

Redefine prolapse repair for your patients with a regenerative autologous graft system.
Contact us
Backed by over 400 procedures based on our preliminary findings with zero reported adverse events, SmartFem’s regenerative autologous graft system is redefining pelvic organ prolapse repair with accelerated healing and personalised, biologically compatible support.

The technology promotes collagen synthesis and augments connective tissue both biologically and mechanically.

Download our research summary
Clinicians reviewing a laptop

Why clinicians are adopting SmartFem

SmartFem’s Victoria Graft System (VGS) is designed for real-world surgical practice and real patient outcomes.

Compatible with anterior and posterior repairs, SmartFem is a non-synthetic, non-animal and non-hormonal approach that offers:

  • Accelerated healing and tissue regeneration
  • Biomechanical support with clinically validated tensile strength
  • Autologous graft – eliminates rejection risk (uses the patient’s own blood)

How the SmartFem system works

The SmartFem VGS system produces an implantable, autologous blood graft intraoperatively.

The key steps are:
A small blood sample is collected
Blood collection

Patient's venous blood is drawn

It’s processed using a centrifuge
Centrifugation

separates bioactive components

Two soft-tissue grafts are created during surgery
Graft preparation

Processed to the optimal shape/volume

Grafts are applied to reinforce the repair site
Surgical implantation

Applied to the prolapse repair site

The body naturally integrates the graft over coming weeks as it heals
Postoperative care

Supports rapid integration and healing

Professional resources

Clinicians receive immediate access to:

  • Surgical technique guides
  • Centrifuge protocol and preparation steps
  • Patient information sheets
  • Support from SmartFem clinical advisors

These resources are designed for fast onboarding with minimal disruption to your existing workflow.

Talk to a SmartFem clinical advisor

Help shape the next generation of prolapse repair

We invite qualified clinicians to collaborate with us by:
  • Trialling the Victoria Graft System in native tissue repair
  • Joining post-market surveillance and data collection programs
  • Sharing clinical insights to inform ongoing product development
Collaborate with us

Clinical research and evidence

SmartFem has been under clinical development since 2018.

Based on our preliminary findings:

  • Over 400 women have been treated, with preliminary results indicating >85% success at 12 months and no reported adverse events
  • Healing time has been accelerated by up to 50% by neovascularisation and fibroblast activity producing collagen
  • In-vitro human tissue studies show consistent mechanical strength, suitable porosity and biocompatibility
Clinical research - image of dna strand
Group photo, people at the back are blurred, smiling lady at the front in focus

Lead your field

SmartFem’s autologous graft system is clinically evaluated to support improved effectiveness and healing outcomes in native tissue prolapse repair.

If you’d like to incorporate the Victoria Graft System into your surgical practice, please contact us. A SmartFem clinical advisor will be in touch with product information and onboarding resources.

Register your interest

FAQs for clinicians

empty

No. It is a non-synthetic autologous graft derived from the patient’s own blood.

No. It’s used as an adjunct — not a replacement — and fits seamlessly into existing procedures.

We provide practical onboarding materials, including illustrated surgical guides and in-theatre support.

Yes. It is applicable across prolapse types, including anterior and posterior.

Yes. A full clinical dossier is available on request. Contact us to begin the conversation.

Yes. The VGS has been assessed by the Therapeutic Goods Administration (TGA) for safety, quality, and efficacy and meets all requirements to be supplied in Australia. This ensures the product complies with Australia’s highest regulatory standards for medical devices and is listed on the Australian Register of Therapeutic Goods (ARTG #464666).

Download research summary